MBX Biosciences (MBX) Income from Continuing Operations (2023 - 2026)
MBX Biosciences (MBX) reported Income from Continuing Operations of 102028000.0 for Q1 2026, down 277.35% on a YoY basis from 57529051.22 in Q1 2025, and down 584.29% sequentially from 14910000.0 in Q4 2025.
MBX Biosciences (MBX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Income from Continuing Operations data on file, last reported at 102028000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 277.35% year-over-year to 102028000.0; the trailing twelve-month figure through Mar 2026 stood at 213654000.0 (down 181.93% YoY), and the FY2025 full-year result was 184722000.0, down 78.69% from the prior year.
- Income from Continuing Operations slipped to 102028000.0 in Q1 2026, from 14910000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10936000.0 in Q3 2023 to a low of 102028000.0 in Q1 2026.
- A 4-year average of 29848181.82 and a median of 16770000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations increased 13.78% in 2024 and sank 277.35% in 2026, its largest moves.
- Tracing MBX's Income from Continuing Operations over 4 years: stood at 14480000.0 in 2023, then gained by 13.78% to 12484000.0 in 2024, then declined by 19.43% to 14910000.0 in 2025, then tumbled by 584.29% to 102028000.0 in 2026.
- Business Quant data shows MBX's Income from Continuing Operations at 102028000.0 in Q1 2026, 14910000.0 in Q4 2025, and 61935000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | -102.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.03 Mn |
| Dec 31, 2025 | -14.91 Mn |
| Sep 30, 2025 | -61.94 Mn |
| Jun 30, 2025 | -34.78 Mn |
| Mar 31, 2025 | -27.04 Mn |
| Dec 31, 2024 | -12.48 Mn |
| Sep 30, 2024 | -19.49 Mn |
| Jun 30, 2024 | -16.77 Mn |
| Mar 31, 2024 | -13.48 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -10.94 Mn |